|
|
2530 Meridian Parkway
Durham, NC 27713 United States
phone:919 855-2100
fax:(919) 806-4417
|
|
| Symbol |
OXBT |
| Exchange |
NASDAQ |
| Founded |
1990 |
| Employees |
24 |
|
|
| www.oxybiomed.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development stage company developing cosmetic, topical and intravenous products that deliver oxygen to tissues |
|
| Management |
| Chris Stern, Chairman and CEO; Michael B. Jebsen, Chief Financial Officer; Gerald Klein, Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| oxygen therapeutics, Oxycyte, Dermacyte, oxygen carriers |
|
|
|
| Description |
|
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery. This year, the company launched its DERMACYTE line of oxygen-rich skin care products. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing. More information is available at www.oxybiomed.com or www.buydermacyte.com. |
|
| Products / Services |
OXYCYTE, DERMACYTE
|
|
| Technology / Differentiation |
| The company's lead drug is Oxycyte, a perfluorocarbon therapeutic oxygen carrier, designed to enhance oxygen delivery to damaged tissues. Using Oxycyte technology, the company has been able to formulate the product into an emulsion, lotions and gels. Oxycyte emulsion molecules are about 1/50th the size of red blood cells and able to flow into small capillaries and around damaged tissue. As an intravenous emulsion, Oxycyte
can carry many times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues. It is the basis for all of the products and indications in the company's pipeline. |
|
| Market / Customers |
Cosmetic and beauty industry for anti-wrinkle and anti-aging skin care products; Traumatic Brain Injury; Decompressoin Sickness; Wound healing
|
|
| Status |
| Oxycyte is in Phase II-b trials in Switzerland and Israel as a treatment for Traumatic Brain Injury
Cosmetic/OTC: (Dermacyte) The company sells two products under the DERMACYTE brand name: One is a concentrated spot treament for facial lines, wrinkles and the other is a lower-concentration Eye Complex for the contour around your eye.
Preclinical studies are underway or in development for wound and dermatological indications. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
